Journal
MOLECULAR ASPECTS OF MEDICINE
Volume 84, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.mam.2021.101044
Keywords
MWC theory; Allosteric regulation; Synaptic receptors; Nicotinic acetylcholine receptor; Neuropharmacology; Brain disease; Thermodynamic modeling; Potency; Efficacy; Selectivity; Modeling; Molecular dynamics; Binding affinity calculations
Funding
- European Union [945539]
- French National Research Agency [ANR-18-CE11-0015]
- Agence Nationale de la Recherche (ANR) [ANR-18-CE11-0015] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
This article proposes an extension and further development of the Monod-Wyman-Changeux model to investigate the allosteric transitions of regulatory proteins in brain communications. The study focuses on neurotransmitters receptors, specifically the nicotinic acetylcholine receptor (nAChR) as a model. The research provides a new, explicit formulation for the modulation factors of these receptors, allowing for the design of neuroactive compounds with controlled pharmacological profiles.
We propose an extension and further development of the Monod-Wyman-Changeux model for allosteric transitions of regulatory proteins to brain communications and specifically to neurotransmitters receptors, with the nicotinic acetylcholine receptor (nAChR) as a model of ligand-gated ion channels. The present development offers an expression of the change of the gating isomerization constant caused by pharmacological ligand binding in terms of its value in the absence of ligands and several modulation factors, which vary with orthosteric ligand binding (agonists/antagonists), allosteric ligand binding (positive allosteric modulators/negative allosteric modulators) and receptor desensitization. The new - explicit - formulation of such modulation factors, provides expressions for the pharmacological attributes of potency, efficacy, and selectivity for the modulatory ligands (including endogenous neurotransmitters) in terms of their binding affinity for the active, resting, and desensitized states of the receptor. The current formulation provides ways to design neuroactive compounds with a controlled pharmacological profile, opening the field of computational neuro-pharmacology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available